drugset / Trial / NCT01585298

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

NCT01585298

Phase 4 Completed 6998 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.

Timeline

Start
2012-04-29
Primary completion
2016-12-12
Completion
2016-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fingolimod Small molecule 0.5 mg Oral

Indications